{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:40:56Z","timestamp":1783028456805,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Pasireotide is a novel therapeutic option for patients with acromegaly resistant to first-generation somatostatin receptor ligands. To date, real-life data are still scant, therefore, the aim of the current study is to evaluate the impact of long-term pasireotide therapy on disease control, pituitary tumor size, gluco-insulinemic and lipid profile in a real-life setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective study of data prospectively collected, evaluating hormonal, tumoral, and metabolic data of 28 patients with acromegaly administered with pasireotide in a pituitary tertiary referral center.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Within the first 12\u00a0months of treatment, 70.4% of patients achieved normal IGF-I levels, which\u00a0was maintained at 36-month evaluation\u00a0in these responders patients. Patients who started with pasireotide 60\u00a0mg monthly exhibited significantly lower IGF-I levels after 36\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.05) as compared to patients administered first with pasireotide 20 or 40\u00a0mg monthly. The maximal tumoral diameter was significantly decreased after 12\u00a0months of pasireotide (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and a further reduction was registered throughout the following months, with 41.2% of patients achieving a significant reduction (&gt;\u200925% of baseline measurement) after 36\u00a0months of treatment. Fasting glucose significantly increased during the first 6\u00a0months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) with a gradual rise in diabetes prevalence during the following months, resulting diabetes prevalence after 36\u00a0months of pasireotide significantly increased compared to baseline (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), although with glycated hemoglobin levels within the normal range. Diabetes was managed using oral glucose-lowering drugs or glucagon-like peptide 1 agonists, with no patient requiring insulin therapy. Pasireotide improved lipid profile, mainly during the first 12\u00a0months of treatment, by increasing HDL and decreasing triglycerides levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pasireotide is effective and safe in the long-term. Hyperglycemia is a common event and is manageable even without insulin treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-023-02299-7","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T17:03:29Z","timestamp":1711472609000},"page":"1887-1901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-9328","authenticated-orcid":false,"given":"R.","family":"Pirchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-3419","authenticated-orcid":false,"given":"R. S.","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4483-0652","authenticated-orcid":false,"given":"A.","family":"Vergura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"R.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-266X","authenticated-orcid":false,"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"2299_CR1","doi-asserted-by":"crossref","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R. (2019) Acromegaly. Nat Rev Dis Primers Mar 5 (1):20","DOI":"10.1038\/s41572-019-0071-6"},{"key":"2299_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S (2020) Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"Suppl 1","key":"2299_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P (2004) (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47\u201350. https:\/\/doi.org\/10.1159\/000080741","journal-title":"Neuroendocrinology"},{"key":"2299_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2007.09.006","author":"HA Schmid","year":"2008","unstructured":"Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. https:\/\/doi.org\/10.1016\/j.mce.2007.09.006","journal-title":"Mol Cell Endocrinol"},{"key":"2299_CR5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Res\u00e9ndiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide C2305 Study Group Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide C2402 Study Group Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2299_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1182-4","author":"M Fleseriu","year":"2017","unstructured":"Fleseriu M, Rusch E, Geer EB (2017) ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. https:\/\/doi.org\/10.1007\/s12020-016-1182-4","journal-title":"Endocrine"},{"key":"2299_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0677-y","author":"A Colao","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R (2016) The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. https:\/\/doi.org\/10.1007\/s11102-015-0677-y","journal-title":"Pituitary"},{"key":"2299_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.633944","author":"P Witek","year":"2021","unstructured":"Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Lu\u017aniak A, Jawiarczyk-Przyby\u0142owska A, Ka\u0142u\u017cny M (2021) The Effect of 6 Months\u2019 Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2021.633944","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2299_CR10","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0762","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"key":"2299_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02782-2","author":"A Akirov","year":"2021","unstructured":"Akirov A, Gorshtein A, Dotan I, Khazen NS, Pauker Y, Gershinsky M, Shimon I (2021) Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine. https:\/\/doi.org\/10.1007\/s12020-021-02782-2","journal-title":"Endocrine"},{"key":"2299_CR12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR13","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02341","author":"AN Paisley","year":"2007","unstructured":"Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ (2007) Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/eje.1.02341","journal-title":"Eur J Endocrinol"},{"key":"2299_CR14","volume-title":"Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation part 1\u2014diagnosis and classification of diabetes mellitus","author":"World Health Organization","year":"1999","unstructured":"World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation part 1\u2014diagnosis and classification of diabetes mellitus. World Health Organization, Geneva"},{"issue":"7","key":"2299_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"issue":"3","key":"2299_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0168-8227(99)00116-3","volume":"47","author":"M Gutt","year":"2000","unstructured":"Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB (2000) Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 47(3):177\u2013184. https:\/\/doi.org\/10.1016\/s0168-8227(99)00116-3","journal-title":"Diabetes Res Clin Pract"},{"key":"2299_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner \u017d, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group (2016) ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"key":"2299_CR18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3213","author":"L Berglund","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF (2012) Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2011-3213","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2299_CR19","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1210\/jc.2009-0941","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94(10):3746\u20133756. https:\/\/doi.org\/10.1210\/jc.2009-0941","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad378","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X, Santos E, Magalh\u00e3es J, Wildemberg LE (2023) Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years\u2019 single-center real-world experience. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad378","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR21","doi-asserted-by":"crossref","unstructured":"Araujo-Castro M, Pian H, Ruz-Caracuel I, Acitores Cancela A, Pascual-Corrales E, Rodr\u00edguez Berrocal V. (2021 ) Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas. Endocr Connect. Jan;10(1):102\u2013109;cStevenaert A, Beckers A. Presurgical Octreotide: treatment in acromegaly. Metabolism. 1996 Aug;45(8 Suppl 1):72\u20134","DOI":"10.1530\/EC-20-0414"},{"key":"2299_CR22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1093","author":"JS Bevan","year":"2005","unstructured":"Bevan JS (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2004-1093","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0315","author":"SM Carlsen","year":"2008","unstructured":"Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J (2008) Preoperative Octreotide Treatment of Acromegaly study group. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2008-0315","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR24","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0361","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect. https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr Connect"},{"key":"2299_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02186-1","author":"G Corica","year":"2023","unstructured":"Corica G, Pirchio R, Milioto A, Nista F, Arecco A, Mattioli L, Auriemma RS, Cocchiara F, Pivonello R, Colao A, Ferone D, Gatto F (2023) Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02186-1","journal-title":"J Endocrinol Invest"},{"key":"2299_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-2952(99)00010-6","author":"Y Zambre","year":"1999","unstructured":"Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, Taylor JE, Coy DH, Van Schravendijk C, Schuit F, Pipeleers DG, Eizirik DL (1999) Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/s0006-2952(99)00010-6","journal-title":"Biochem Pharmacol"},{"key":"2299_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1578","author":"V Singh","year":"2007","unstructured":"Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Pl\u00f6ckinger U, Strowski MZ (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2006-1578","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2299_CR28","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446\u20133453. https:\/\/doi.org\/10.1210\/jc.2013-1771","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.011","author":"A Breitschaft","year":"2014","unstructured":"Breitschaft A, Hu K, Hermosillo Res\u00e9ndiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.011","journal-title":"Diabetes Res Clin Pract"},{"key":"2299_CR30","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0296","author":"P Wolf","year":"2022","unstructured":"Wolf P, Dormoy A, Maione L, Salenave S, Young J, Kamenick\u00fd P, Chanson P (2022) Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Endocr Connect. https:\/\/doi.org\/10.1530\/EC-22-0296","journal-title":"Endocr Connect"},{"key":"2299_CR31","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-11-0224","author":"HA Schmid","year":"2012","unstructured":"Schmid HA, Brueggen J (2012) Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol. https:\/\/doi.org\/10.1530\/JOE-11-0224","journal-title":"J Endocrinol"},{"key":"2299_CR32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02566","author":"A Cozzolino","year":"2018","unstructured":"Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM (2018) Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2017-02566","journal-title":"J Clin Endocrinol Metab"},{"key":"2299_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0365-5","author":"C Giordano","year":"2012","unstructured":"Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS, Grasso LF, Galluzzo A, Colao A (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary. https:\/\/doi.org\/10.1007\/s11102-011-0365-5","journal-title":"Pituitary"},{"key":"2299_CR34","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02112","author":"A Colao","year":"2006","unstructured":"Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/eje.1.02112","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2299_CR35","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","volume":"55","author":"RS Auriemma","year":"2017","unstructured":"Auriemma RS, Grasso LF, Galdiero M, Galderisi M, Pivonello C, Simeoli C, De Martino MC, Ferrigno R, Negri M, de Angelis C, Pivonello R, Colao A (2017) Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55(3):872\u2013884. https:\/\/doi.org\/10.1007\/s12020-016-0995-5","journal-title":"Endocrine"},{"key":"2299_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01980-7","author":"R Pirchio","year":"2023","unstructured":"Pirchio R, Auriemma RS, Montini ME, Vergura A, Pivonello R, Colao A (2023) Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-022-01980-7","journal-title":"J Endocrinol Invest"},{"key":"2299_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0483-3","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary. https:\/\/doi.org\/10.1007\/s11102-013-0483-3","journal-title":"Pituitary"},{"key":"2299_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0615-y","author":"SL Samson","year":"2016","unstructured":"Samson SL (2016) Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. Drugs. https:\/\/doi.org\/10.1007\/s40265-016-0615-y","journal-title":"Drugs"},{"key":"2299_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.06.006","author":"X Chen","year":"2014","unstructured":"Chen X, Shen G, Jiang J, Liu H, Hu K, Darstein C, Lasher J, Hu P (2014) Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. Clin Ther. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.006","journal-title":"Clin Ther"},{"key":"2299_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01077-8","author":"C Simeoli","year":"2020","unstructured":"Simeoli C, Ferrigno R, De Martino MC, Iacuaniello D, Papa F, Angellotti D, Pivonello C, Patalano R, Negri M, Colao A, Pivonello R (2020) The treatment with pasireotide in Cushing\u2019s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-019-01077-8","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02299-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:09:09Z","timestamp":1721786949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02299-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02299-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AC has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck and Novo Nordisk; consultant for Novartis, Ipsen, Pfizer, and received honoraria from Novartis, Ipsen and Pfizer beyond the confines of this work. RPiv has been Principal Investigator of Clinical and\/or Translational Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB, Janssen Cilag, Camurus, Strongbridge, and Pfizer; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA, Strongbridge Biopharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring, Strongbridge Biopharma, Recordati, Corcept Therapeutics, Crinetics Pharmaceuticals, ARH Healthcare, Biohealth Italia, Italfarmaco; and has received fees and honoraria for presentations from Novartis, Shire, Pfizer and Recordati beyond the confines of this work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study involved human participants. The study was conducted in accordance with the Declaration of Helsinki and \u201cFederico II\u201d Ethics Committee approved the study protocol (193\/16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The patients included in the current study provided written informed consent with respect to a confidentiality statement of data collection according to the Italian privacy policy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}